Hypoparathyroidism: disease update and new methods of treatment
https://doi.org/10.14341/serg2017270-80
Abstract
Hypoparathyroidism is characterized by hypocalcaemia and normal or low levels of parathyroid hormone (PTH). The most common cause of hypoparathyroidism is damage to the parathyroid glands during anterior neck surgery. Conventional management of hypoparathyroidism is focused upon maintaining the serum calcium with oral calcium and active vitamin D, often requiring high doses and giving rise to concerns about long-term consequences including extracellular calcification and kidney stones. With current treatment, patients may suffer from large swings in serum calcium and are at a substantial risk of chronic renal failure, extracellular calcification. Replacement therapy of recombinant human PTH(1-84) can open up new opportunities for better control and improvement of quality of life.
About the Authors
Tatiana A. Grebennikova
https://www.endocrincentr.ru/doctors/grebennikova-tatyana-alekseevna
Russian Federation
Endocrinology Research Centre
Russian Federation
MD
Zhanna E. Belaya
https://www.endocrincentr.ru/doctors/belaya-zhanna-evgenevna
Russian Federation
Endocrinology Research Centre
Russian Federation
MD, PhD, Professor
Galina A. Melnichenko
https://www.endocrincentr.ru/rukovodstvo/melnichenko-galina-afanasevna
Russian Federation
Endocrinology Research Centre
Russian Federation
MD, PhD, Professor
References
1. Bilezikian JP, Khan A, Potts JT, Jr., et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011;26(10):2317-2337. doi: 10.1002/jbmr.483.
2. Abate EG, Clarke BL. Review of hypoparathyroidism. Front Endocrinol (Lausanne). 2016;7:172. doi: 10.3389/fendo.2016.00172.
3. Hadker N, Egan J, Sanders J, et al. Understanding the burden of illness associated with hypoparathyroidism reported among patients in the PARADOX study. Endocr Pract. 2014;20(7):671-679. doi: 10.4158/EP13328.OR.
4. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Postsurgical hypoparathyroidism – risk of fractures, psychiatric diseases, cancer, cataract, and infections. J Bone Miner Res. 2014;29(11):2504-2510. doi: 10.1002/jbmr.2273.
5. Clarke BL, Brown EM, Collins MT, et al. Epidemiology and diagnosis of hypoparathyroidism. J Clin Endocrinol Metab. 2016;101(6):2284-2299. doi: 10.1210/jc.2015-3908.
6. Powers J, Joy K, Ruscio A, Lagast H. Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J Bone Miner Res. 2013;28(12): 2570-2576. doi: 10.1002/jbmr.2004.
7. Hauch A, Al-Qurayshi Z, Randolph G, Kandil E. Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. Ann Surg Oncol. 2014; 21(12):3844-3852. doi: 10.1245/s10434-014-3846-8.
8. Кузнецов Н.С., Симакина О.В., Ким И.В. Предикторы послеоперационного гипопаратиреоза после тиреоидэктомии и методы его лечения. // Клиническая и экспериментальная тиреоидология. – 2012. – Т. 8. – №2. – С. 20–30. [Kuznetsov NS, Simakina OV, Kim IV. Predictors of postoperative hypoparathyroidism after thyroidectomy and methods of treatment. Clinical and experimental thyroidology. 2012; 8(2):20-30. (In Russ.)]. doi: 10.14341/ket20128220-30.
9. Stack BC Jr, Bimston DN, Bodenner DL, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Disease state clinical review: postoperative hypoparathyroidism – definitions and management. Endocr Pract. 2015;21(6):674-685. doi: 10.4158/EP14462.DSC.
10. Cirocchi R, Trastulli S, Randolph J, et al. Total or near-total thyroidectomy versus subtotal thyroidectomy for multinodular non-toxic goitre in adults. Cochrane Database Syst Rev. 2015;(8):CD010370. doi: 10.1002/14651858.CD010370.pub2.
11. Ritter K, Elfenbein D, Schneider DF, et al. Hypoparathyroidism after total thyroidectomy: incidence and resolution. J Surg Res. 2015;197(2):348-353. doi: 10.1016/j.jss.2015.04.059.
12. Bollerslev J, Rejnmark L, Marcocci C, et al. European Society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015; 173(2):G1-20. doi: 10.1530/EJE-15-0628.
13. Kirkby-Bott J, Markogiannakis H, Skandarajah A, et al. Preoperative vitamin D deficiency predicts postoperative hypocalcemia after total thyroidectomy. World J Surg. 2011;35(2):324-330. doi: 10.1007/s00268-010-0872-y.
14. Erbil Y, Barbaros U, Temel B, et al. The impact of age, vitamin D(3) level, and incidental parathyroidectomy on postoperative hypocalcemia after total or near total thyroidectomy. Am J Surg. 2009;197(4):439-446. doi: 10.1016/j.amjsurg.2008.01.032.
15. Sam AH, Dhillo WS, Donaldson M, et al. Serum parathyroid hormone is not an accurate predictor of postthyroidectomy hypocalcemia in vitamin D – deficient patients: a pilot study. Clin Chem. 2011;57(8):1206-1207. doi: 10.1373/clinchem.2011.162909.
16. Marcocci C, Bollerslev J, Khan AA, Shoback DM. Medical management of primary hyperparathyroidism: proceedings of the fourth international workshop on the management of asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab. 2014;99(10):3607-3618. doi: 10.1210/jc.2014-1417.
17. Орлова Е.М., Созаева Л.С., Маказан Н.В. Гипопаратиреоз у детей: клинические варианты, современная диагностика и лечение (лекция для врачей). // Доктор.Ру. – 2014. – Т. 11. – №99. – С. 27-30. [Orlova EM, Sozaeva LS, Makazan NV. Hypoparathyroidism in children: clinical forms, modern diagnosis, and treatment lecture for doctors. Doctor Ru. 2014;11(99):27-30. (In Russ.)].
18. Page C, Strunski V. Parathyroid risk in total thyroidectomy for bilateral, benign, multinodular goitre: report of 351 surgical cases. J Laryngol Otol. 2007;121(3):237-241.
19. doi: 10.1017/S0022215106003501.
20. Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med. 2008;359(4):391-403. doi: 10.1056/NEJMcp0803050.
21. Schaaf M, Payne CA. Effect of diphenylhydantoin and phenobarbital on overt and latent tetany. N Engl J Med. 1966;274(22):1228-1233. doi: 10.1056/NEJM196606022742203.
22. Hoffman E. The Chvostek sign; a clinical study. Am J Surg. 1958;96(1):33-37.
23. Fonseca OA, Calverley JR. Neurological manifestations of hypoparathyroidism. Arch Intern Med. 1967;120(2):202-206.
24. Ballane GT, Sfeir JG, Dakik HA, et al. Use of recombinant human parathyroid hormone in hypocalcemic cardiomyopathy. Eur J Endocrinol. 2012;166(6):1113-1120. doi: 10.1530/EJE-11-1094.
25. Mitchell DM, Regan S, Cooley MR, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 2012;97(12):4507-4514. doi: 10.1210/jc.2012-1808.
26. Minisola S, Dionisi S, Pacitti MT, et al. Gender differences in serum markers of bone resorption in healthy subjects and patients with disorders affecting bone. Osteoporos Int. 2002;13(2):171-175.
27. Christen P, Ito K, Muller R, et al. Patient-specific bone modelling and remodelling simulation of hypoparathyroidism based on human iliac crest biopsies. J Biomech. 2012;45(14): 2411-2416. doi: 10.1016/j.jbiomech.2012.06.031.
28. Rubin MR, Dempster DW, Zhou H, et al. Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res. 2008;23(12):2018-2024. doi: 10.1359/jbmr.080803.
29. Cusano NE, Rubin MR, Irani D, et al. Use of parathyroid hormone in hypoparathyroidism. J Endocrinol Invest. 2013;36(11):1121-1127. doi: 10.1007/bf03346763.
30. Arlt W, Fremerey C, Callies F, et al. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol. 2002;146(2):215-222. doi: 10.1530/eje.0.1460215.
31. Lourida I, Thompson-Coon J, Dickens CM, et al. Parathyroid hormone, cognitive function and dementia: a systematic review. PLoS One. 2015;10(5):e0127574. doi: 10.1371/journal.pone.0127574.
32. Nikiforuk G, Fraser D, Poyton HG, McKendry JB. Calcific bridging of dental pulp caused by iatrogenic hypercalcemia. Report of a case. Oral Surg Oral Med Oral Pathol. 1981; 51(3):317-319.
33. Bilezikian JP, Brandi ML, Cusano NE, et al. Management of hypoparathyroidism: present and future. J Clin Endocrinol Metab. 2016;101(6):2313-2324. doi: 10.1210/jc.2015-3910.
34. Holick MF. Vitamin D deficiency. N Engl J Med. 2007; 357(3):266-281. DOI: 10.1056/NEJMra070553.
35. Белая Ж.Е., Рожинская Л.Я. Падения – важная социальная проблема пожилых людей. Основные механизмы развития и пути предупреждения. // РМЖ. – 2009. – Т. 17. – №24. – С. 1614-1619. [Belaya ZE, Rozhinskaya LY. Padeniya – vazhnaya sotsial'naya problemapozhilykh lyudei. Osnovnye mekhanizmy razvitiya i puti preduprezhdeniya. Russian medical journal. 2009;17(24):1614-1619. (In Russ.)].
36. Пигарова Е.А., Рожинская Л.Я., Белая Ж.Е., и др. Клинические рекомендации Российской ассоциации эндокринологов по диагностике, лечению и профилактике дефицита витамина D у взрослых. // Проблемы эндокринологии. – 2016. – Т. 62. – №4. – С. 60-84. [PigarovaEA, Rozhinskaya LY, Belaya JE, et al. Russian Association of Endocrinologists recommendations for diagnosis, treatment and prevention of vitamin D deficiency in adults. Problems of Endocrinology. 2016;62(4):60-84. (In Russ.)]. doi: 10.14341/probl201662460-84.
37. Garrahy A, Murphy MS, Sheahan P. Impact of postoperative magnesium levels on early hypocalcemia and permanent hypoparathyroidism after thyroidectomy. Head Neck. 2016;38(4):613-619. doi: 10.1002/hed.23937.
38. Cusano NE, Rubin MR, Bilezikian JP. Parathyreoid hormone therapy for hypoparathyroidism. Best Pract Res Clin Endocrinol Metab. 2015;29(1):47-55. doi: 10.1016/j.beem.2014.09.001.
39. Brandi ML, Bilezikian JP, Shoback D, et al. Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metab. 2016;101(6):2273-2283. doi: 10.1210/jc.2015-3907.
40. Белая Ж.Е., Рожинская Л.Я. Анаболическая терапия остеопороза. Терипаратид: эффективность, безопасность и область применения. // Остеопороз и остеопатии. – 2013. – Т. 16. – №2. – С. 32-40. [Belaya ZhE, Rozhinskaya LY. Anabolicheskaya terapiya osteoporoza.Teriparatid: effektivnost', bezopasnost' i oblast' primeneniya. Osteoporosis and osteopathy. 2013;16(2):32-40. (In Russ.)]. doi: 10.14341/osteo2013232-40.
41. Гребенникова Т.А., Ларина И.И., Белая Ж.Е., Рожинская Л.Я. Клинический случай применения терипаратида для лечения послеоперационного гипопаратиреоза с неконтролируемой гипокальциемией в сочетании с тяжелым остеопорозом. // Остеопороз и остеопатии. – 2016. – Т. 19. – №3. – С. 37–40. [Grebennikova TA, Larina II, Belaya ZhE, Rozhinskaya LY. Clinical case of teriparatide use for the treatment of postoperative hypoparathyroidism with uncontrolled hypocalcemia combined with severe osteoporosis. Osteoporosis and osteopathy.2016;19(3):37-40. (In Russ.)]. doi: 10.14341/osteo2016337-40.
42. Winer KK, Yanovski JA, Sarani B, Cutler GB, Jr. A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism. J Clin Endocrinol Metab. 1998;83(10):3480-3486. doi: 10.1210/jcem.83.10.5185.
43. Winer KK, Ko CW, Reynolds JC, et al. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab. 2003;88(9):4214-4220. doi: 10.1210/jc.2002-021736.
44. Winer KK, Sinaii N, Reynolds J, et al. Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J Clin Endocrinol Metab. 2010; 95(6):2680-2688. doi: 10.1210/jc.2009-2464.
45. Winer KK, Zhang B, Shrader JA, et al. Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab. 2012;97(2):391-399. doi: 10.1210/jc.2011-1908.
46. Winer KK, Fulton KA, Albert PS, Cutler GB, Jr. Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism. J Pediatr. 2014;165(3):556-563 e551. doi: 10.1016/j.jpeds.2014.04.060.
47. Natpara [package insert]. Bedminster, NJ: NPS Pharmaceuticals, Inc; 2015. Available on: http://ir.npsp.com/releasedetail.cfm?releaseid=892722.
48. Clarke BL, Kay Berg J, Fox J, et al. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study. Clin Ther. 2014;36(5):722-736. doi: 10.1016/j.clinthera.2014.04.001.
49. Wang H, Liu J, Yin Y, et al. Recombinant human parathyroid hormone related protein 1-34 and 1-84 and their roles in osteoporosis treatment. PLoS One. 2014;9(2):e88237. doi: 10.1371/journal.pone.0088237.
50. Sikjaer T, Amstrup AK, Rolighed L, et al. PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment. J Bone Miner Res. 2013;28(10): 2232-2243. doi: 10.1002/jbmr.1964.
51. Rubin MR, Sliney J, Jr., McMahon DJ, et al. Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int. 2010;21(11):1927-1934. doi: 10.1007/s00198-009-1149-x.
52. Sikjaer T, Rejnmark L, Rolighed L, et al. The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res. 2011;26(10):2358-2370. doi: 10.1002/jbmr.470.
53. Cusano NE, Rubin MR, McMahon DJ, et al. Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metab. 2013;98(1):137-144. doi: 10.1210/jc.2012-2984.
54. Rubin MR, Dempster DW, Sliney J, Jr., et al. PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res. 2011;26(11):2727-2736. doi: 10.1002/jbmr.452.
55. Mannstadt M, Clarke BL, Vokes T, et al. Efficacy and safety of recombinant human parathyroid hormone (1–84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 2013;1(4):275-283. doi: 10.1016/s2213-8587(13)70106-2.
56. Sikjaer T, Rolighed L, Hess A, et al. Effects of PTH(1–84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos Int. 2014;25(6):1717-1726. doi: 10.1007/s00198-014-2677-6.
57. Cusano NE, Rubin MR, McMahon DJ, et al. PTH(1–84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. J Clin Endocr Metab. 2014;99(10):3694-3699. doi: 10.1210/jc.2014-2267.
58. Andrews EB, Gilsenan AW, Midkiff K, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 years. J Bone Miner Res. 2012;27(12):2429-2437. doi: 10.1002/jbmr.1768.
59. Cipriani C, Irani D, Bilezikian JP. Safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res. 2012;27(12):2419-2428. doi: 10.1002/jbmr.1800.
60. Lakatos P, Bajnok L, Lagast H, Valkusz Z. An open-label extension study of parathyroid hormone RHPTH(1-84) in adults with hypoparathyroidism. Endocr Pract. 2016;22(5): 523-532. doi: 10.4158/EP15936.OR.
Supplementary files
|
|
1. Таблица 1. Наследственные причины гипопаратиреоза | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(208KB)
|
Indexing metadata ▾ | |
|
|
2. Таблица 2. Препараты, использующиеся при стандартной схеме терапии гипопаратиреоза | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(39KB)
|
Indexing metadata ▾ | |
Review
For citations:
Grebennikova T.A., Belaya Zh.E., Melnichenko G.A. Hypoparathyroidism: disease update and new methods of treatment. Endocrine Surgery. 2017;11(2):70-80. (In Russ.) https://doi.org/10.14341/serg2017270-80
Views:
15299
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
